Human pharmaceutical products in the environment - The "problem" in perspective

Chemosphere

Volumn 115, Issue 1, 2014, Pages 95-99

  Taylor, David ^a,b   Senac, Thomas ^a,b  

^a WCA ENVIRONMENT LTD   (United Kingdom)

^b SANOFI   (France)

Author keywords

Environment; Pharmaceuticals; Policy; Risk assessment

Indexed keywords

DIMETHYLFORMAMIDE; DRUG PRODUCTS; ENVIRONMENTAL IMPACT; HEALTH RISKS; PUBLIC POLICY;

ANALYTICAL SCIENCE; DIMETHYL FUMARATE; EMERGING CONTAMINANT; ENVIRONMENT; ENVIRONMENTAL CONTAMINANT; ENVIRONMENTAL EXPOSURE; HUMAN PHARMACEUTICALS; TOXICOLOGICAL PROPERTIES;

RISK ASSESSMENT;

ATORVASTATIN; GLYCERYL TRINITRATE; INSULIN; PROPOFOL; WARFARIN; DRUG; POLLUTANT;

DRUG; ENVIRONMENTAL IMPACT; INHIBITOR; ORGANIC COMPOUND; POLICY MAKING; POLLUTION EXPOSURE; RISK ASSESSMENT; TOXICOLOGY;

AQUATIC ENVIRONMENT; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; COST BENEFIT ANALYSIS; DRUG DESIGN; DRUG INDUSTRY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL IMPACT; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR WEIGHT; POLLUTION; RISK ASSESSMENT; WASTE; WASTE WATER MANAGEMENT; ADVERSE EFFECTS; ANALYSIS; ENVIRONMENT; LEGISLATION AND JURISPRUDENCE; POLLUTANT; PROCEDURES;

ENVIRONMENT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 84921636466     PISSN: 00456535     EISSN: 18791298     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2014.01.011     Document Type: Article

References (20)

1. Ayscough, N.J., Fawell, J., Franklin, G., Young, W., 2000. Review of Human Pharmaceuticals in the Environment. UK Environment Agency R&D Technical Report P390.
2. Corcoran J., Winter M.J., Tyler C.R. Pharmaceuticals in the aquatic environment: a critical review of the evidence for health effects in fish. Crit. Rev. Toxicol. 2010, 40:287-304.
3. Cuthbert R., Taggart M.A., Prakash V., Saini M., Swarup D., Upreti S., Mateo R., Chakraborty S.S., Deori P., Green R.E. Effectiveness of action in india to reduce exposure of Gyps vultures to the toxic veterinary drug diclofenac. PLoS ONE 2011, 6:e19069.
4. EMA (European Medicines Agency), 2013. Summary of Opinion (initial authorisation) Tecfidera Dimethyl fumarate (EMA/167897/2013).
5. EU (European Union), 2012. Commission Regulation (EU) No. 412/2012 of 15 May 2012 amending Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Official Journal L128 1-3.
6. Grung, M., Eldbjørg, S., Heimstad, M.M., Schlabach, M., Svenson, A., Thomas, K., Woldegiorgis, A., 2007. Human and Veterinary Pharmaceuticals, Narcotics, and Personal Care Products in the Environment. SFT, Report TA-2325/2007.
7. HMA (Heads of Medicines Agency), 2012. HMA/EMA Guidance Document on the Identification of Commercially Confidential Information and Personal Data within the Structure of the Marketing Authorisation (MA) Application: Release of Information after the Granting of a Marketing Authorisation. European Medicines Agency, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/03/news_detail_001478.jsp%26mid=WC0b01ac058004d5c1.
8. Holm G., Talbot J., Taylor D., Snape J.R., Murray-Smith R., Sörme P. Ecopharmacovigilance - what could it mean in practice?. Drug Safety 2013, 36:533-546.
9. Jobling S., Owen R. Ethinyl estradiol: bitter pill for the precautionary principle. Late Lessons from Early Warnings: Science, Precaution, Innovation 2013, 311-339. European Environment Agency, (Chapter 13). D. Gee (Ed.).
10. Larsson D.G.J., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard. Mater. 2007, 148:751-755.
11. Mattson, B., Nasmen I., Strom, J., 2008, Sweden's voluntary environmental drug classification system. RAJ Pharma March, 138-153.
12. Murray-Smith R.J., Coombe V.T., Haag Grönlund M., Waern F., Baird J.A. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: an environmental quality standard approach. Integr. Environ. Assess. Manage. 2012, 8:320-330.
13. Park, J., 2005. Pharmaceuticals in the Environment and Management Approaches in Korea. Korea Environment Institute Report KEI 2005 RE-12.
14. Purdom C.E., Hardiman P.A., Bye V.V.J., Eno N.C., Tyler C.R., Sumpter J.P. Estrogenic effects of effluents from sewage treatment works. Chem. Ecol. 1994, 8:275-285.
15. Richardson M.L., Bowron J.M. The fate of pharmaceutical chemicals in the aquatic environment. J. Pharm. Pharmacol. 1985, 37:1-12.
16. Roig B. Pharmaceuticals in the Environment: Current Knowledge and Need Assessment to Reduce Presence and Impact 2010, IWA Publishing.
17. SMPA (Swedish Medical Products Agency), 2004. Environmental Effects of Pharmaceuticals, Cosmetics and Hygiene Products. Official report from the Swedish Medical Products Agency.
18. Sumpter J.P., Jobling S. Vitellogenesis as a biomarker of oestrogenic contamination of the aquatic environment. Environ. Health Persp. 1995, 103:173-178.
19. Sumpter J.P., Johnson A.C. 10th anniversary perspective: reflections on endocrine disruption in the aquatic environment: from known knowns to unknown unknowns (and many things in between). J. Environ. Monit. 2008, 10:476-485.
20. Velo G., Moretti U. Ecopharmacovigilance for better health. Drug Safety 2010, 33:963-968.